ICD Research's Idenix Pharmaceuticals, Inc. : Pharmaceuticals and Healthcare - Company Profile, SWOT & Financial Report contains in depth information and data about the company and its operations. The profile contains a company overview, key facts,major products and services, swot analysis, business description, company history, financial analysis, key employees, company locations and subsidiaries, employee biographies as well as competitive benchmarking data.
This report is a crucial resource for industry executives and anyone looking to access key information about Idenix Pharmaceuticals, Inc.
The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Examines and identifies key information and issues about Idenix Pharmaceuticals, Inc. for business intelligence requirements.
Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
Provides data on company financial performance and competitive benchmarking.
The profile also contains information on business operations, company history, major products and services, key employees, locations and subsidiaries.
Reasons To Buy
Quickly enhance your understanding of Idenix Pharmaceuticals, Inc.
Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.
Increase business/sales activities by understanding your competitors’ businesses better.
Recognize potential partnerships and suppliers.
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company, based in the US. The company primarily focuses on the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). Its HCV discovery program focuses on various classes of drugs including nucleoside, nucleotide polymerase inhibitors, protease inhibitors, non-nucleoside polymerase inhibitors, and NS5A inhibitors. The company develops products and drug candidates for the treatment of patients with hepatitis B virus (HBV), human immunodeficiency virus (HIV) type-1, and acquired immune deficiency syndrome (AIDS). The company has a collaboration agreement with Novartis Pharma AG under which, Novartis develops and commercializes its HBV drug telbivudine under the Tyzeka and Sebivo brands. The company conducts its clinical development operations and drug discovery operations in Cambridge, the US and Montpellier, France. Idenix is headquartered in Cambridge, Massachusetts, the US.